Highlights of This Issue 5831

SPECIAL FEATURES

Editorial

5833

Gauging Progress in a Decades-Old Fight

Jesse Potash and Kenneth C. Anderson

CCR Translations

5834

Model T Muscle CARs Can Treat Brain Tumors

Laura A. Johnson

See article p. 5949

CCR New Strategies

5837

New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents

Katherine A. Janeway and Robert G. Maki

CCR Perspectives in Drug Approval

5845

U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma


Molecular Pathways

5850

Molecular Pathways: Tumor Cells Co-opt the Brain-Specific Metabolism Gene CPT1C to Promote Survival

Patrick T. Reilly and Tak W. Mak

Review

5856

The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer

Brian M. Slomovitz and Robert L. Coleman

HUMAN CANCER BIOLOGY

5865

Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis

Carolyn D. Hurst, Fiona M. Platt, Claire F. Taylor, and Margaret A. Knowles

5878

Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas


5888

Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells

Shahriar Koochekpour, Sunipa Majumdar, Gissou Azabdaftari, Kristopher Atwood, Ray Scioneaux, Dhatchayani Subramani, Charles Manhardt, Giovanni D. Lorusso, Stacey S. Willard, Hillary Thompson, Mojiqan Shourideh, Katayoon Rezaei, Oliver Sartor, James L. Mohler, and Robert L. Vessella

5902

Expression of Serotonin Receptors in Human Hepatocellular Cancer

Christopher Soll, Marc-Oliver Rieger, Christian Eugen Oberkofler, Claus Hellerbrand, Peter J. Wild, Michelle L. DeOliveira, and Pierre-Alain Clavien
CANCER THERAPY: PRECLINICAL

5911 Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo Fiona Simpkins, Pedro Hevia-Paez, Jun Sun, Wendy Ullmer, Candace A. Gilbert, Thiago da Silva, Ali Pedram, Ellis R. Levin, Isilkinha M. Reis, Brian Rabinovich, Diana Azzam, Xiang-Xi Xu, Tan A. Ince, Ji-Yeon Yang, Roel G.W. Verhaak, Yiling Lu, Gordon B. Mills, and Joyce M. Slengerland

5924 Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status Maria Joao Baptista, Ana Muntañola, Eva Calpe, Pau Abrissquetà, Olga Salamero, Eva Fernandez, Carles Codony, Eva Giné, Susana G. Kalko, Marta Crespo, and Francesc Bosch

5934 Stichoposide C Induces Apoptosis through the Generation of Ceramide in Leukemia and Colorectal Cancer Cells and Shows In Vivo Antitumor Activity Seong-Hoon Yun, Eun-Seon Park, Sung-Won Shin, Yong-Woo Na, Jin-Young Han, Jin-Sook Jeong, Valeria V. Shastina, Valentin A. Stonik, Joo-In Park, and Jong-Young Kwak


5961 FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51 Nu Zhang, Xinjian Wu, Lixuan Yang, Feizhe Xiao, Heng Zhang, Aidong Zhou, Zhengqiong Huang, and Suyun Huang

CANCER THERAPY: CLINICAL

5972 Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer Dharam J Madhavan, Manuela Zacknick, Markus Wallwiener, Katarina Cuk, Caroline Modugno, Martina Scharpf, Sarah Schwott, Jorg Heil, Andrey Turchinovich, Rongxi Yang, Axel Benner, Sabine Rietdorf, Andreas Trumpp, Christof Sohn, Klaus Pantel, Andreas Schneeweiss, and Barbara Burwinkel

5983 Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study Xia Pu, Yuanqing Ye, Margaret R. Spitz, Liang Wang, Jian Gu, Scott M. Lippman, Michelle A.T. Hildebrandt, Waun Ki Hong, John D. Minna, Jack A. Roth, Ping Yang, and Xifeng Wu

5992 Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer Masanori Terashima, Koji Kitada, Atsushi Ochial, Wataru Ichikawa, Isser Kuraishi, Shinichi Sakuramoto, Hitoshi Katoa, Takeshi Sano, Hiroshi Imamura, and Mitsuhiro Sasaki; for the ACTS-GC Group


IMAGING, DIAGNOSIS, PROGNOSIS

6011 A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stermpak, Frank M. Balis, and Susan M. Blaney
Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors
Yan Xin, Jessica Li, Jenny Wu, Rashell Kinard, Colin D. Weekes, Amita Patnaik, Patricia LoRusso, Rainer Brachmann, Raymond K. Tong, Yibing Yan, Ryan Watts, Shuang Bai, and Priti S. Hegde

Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07)
Richard Cathomas, Christian Rothermundt, Dirk Klingbiel, Lukas Bubendorf, Rolf Jaggi, Daniel C. Betticher, Peter Brauchli, Denise Cotting, Cornelia Droege, Ralph Winterhalder, Daniele Siciliano, Dominik R. Berthold, Miklos Pless, Ralph Schiess, Roger von Moos, and Silke Gillessen; for the Swiss Group for Clinical Cancer Research (SAKK)

Correction: The Use of Quantitative Real-Time Reverse-Transcriptase PCR for 5’ and 3’ Portions of ALK Transcripts to Detect ALK Rearrangements in Lung Cancers
Kendall J. Blumer, Katherine Weilbaecher, and David Piwnica-Worms

Spleen Cells from Young Donors Eradicate Large Tumors—Letter
Laszlo Radvanyi

Spleen Cells from Young Donors Eradicate Large Tumors—Response
Donald A. Rowley, Karin Schreiber, and Hans Schreiber

Bioluminescence Imaging of Prenylation Inhibition—Letter
Philippe Clezardin

Bioluminescence Imaging of Prenylation Inhibition—Response
Kendall J. Blumer, Katherine Weilbaecher, and David Piwnica-Worms
ABOUT THE COVER

Serotonin receptors are expressed in the liver and human hepatocellular cancer (HCC). The cover shows the immunohistochemical staining of the serotonin receptor 1B (HTR1B) in a specimen of human HCC. In a subset of tumors, the expression of HTR1B was significantly increased compared with corresponding nontumor liver tissue of the same patient. The expression of the receptor correlated with a higher proliferation rate and tumor size, suggesting an involvement of serotonin receptors in tumor growth of human HCC. For details, see the article by Soll and colleagues on page 5902 of this issue.